-+ 0.00%
-+ 0.00%
-+ 0.00%

Royalty Pharma buys Zealand Pharma rusfertide economics in USD 100 million deal

PUBT·08/12/2026 20:15:30
Listen to the news
Royalty Pharma buys Zealand Pharma rusfertide economics in USD 100 million deal
  • Royalty Pharma agreed to provide USD 100 million to Zealand Pharma for its economics tied to rusfertide.
  • Deal transfers rights to a 1% royalty on potential global net sales, plus regulatory and commercial milestones.
  • Payment split into USD 50 million at closing, USD 50 million due on the first anniversary.
  • Zealand keeps a 0.25% royalty on annual net global sales above USD 1.5 billion; Royalty Pharma holds 0.75% above that level.
  • FDA set a PDUFA goal date for the rusfertide NDA in Q3 2026; Takeda responsible for global commercialization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121610PRIMZONEFULLFEED9809025) on August 12, 2026, and is solely responsible for the information contained therein.